Literature DB >> 16491266

Evaluation of tetrahydrobiopterin (BH4) as a potential therapeutic agent to treat erectile dysfunction.

Frank Sommer1, Theodor Klotz, Dirk Steinritz, Wilhelm Bloch.   

Abstract

AIM: Nitric oxide (NO)-mediated smooth muscle relaxation causes penile erections. The endothelial NO synthase (eNOS) coenzyme tetrahydrobiopterin (BH4) converts eNOS-mediated catalytic activity from oxygen radical to NO production, improving endothelial function and vascular smooth muscle relaxation.
METHODS: Using quantitative immunohistochemistry, 8-isoprostane and nitrotyrosine concentrations were compared in cavernosal tissue from 17 potent and 7 impotent men, and the effect of single oral doses of BH4 on penile rigidity and tumescence was investigated. The pharmacodynamic effect of single oral doses of BH4 on penile rigidity and tumescence was investigated in a randomized, placebo-controlled, double-blind cross-over fashion in 18 patients with erectile dysfunction (ED) while receiving visual sexual stimulation.
RESULTS: 8-Isoprostane content in endothelium and smooth muscle was significantly higher in impotent patient samples; the level of nitrotyrosine was unchanged in ED patients. Relative to placebo, a single dose of 200 mg BH4 led to a mean increase in duration of > 60% penile rigidity (33.5 min [95% confidence interval (CI): 13.1-49.3] at base and 29.4 min [95% CI: 8.9-42.2] at tip). A 500-mg dose increased the relative duration of > 60% penile rigidity by 36.1 min (95% CI: 16.3-51.8) at the base and 33.7 min (95% CI: 11.4-43.9) at the tip. Treatments were well tolerated.
CONCLUSION: BH4 treatment is suggested to switch eNOS catalytic activity from super-oxide to NO formation, leading to a reduced formation of free radical reaction product 8-isoprostane without alteration of nitrotyrosine. The observed results make BH4 a suitable candidate as an ED treatment through reconstitution of altered catalytic activity of the eNOS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16491266     DOI: 10.1111/j.1745-7262.2006.00122.x

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  6 in total

Review 1.  Hydrogen sulfide in biochemistry and medicine.

Authors:  Benjamin Lee Predmore; David Joseph Lefer; Gabriel Gojon
Journal:  Antioxid Redox Signal       Date:  2012-04-20       Impact factor: 8.401

Review 2.  Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects.

Authors:  Zvonimir S Katusic; Livius V d'Uscio; Karl A Nath
Journal:  Trends Pharmacol Sci       Date:  2008-11-29       Impact factor: 14.819

Review 3.  Gas what: NO is not the only answer to sexual function.

Authors:  G Yetik-Anacak; R Sorrentino; A E Linder; N Murat
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

4.  Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients?

Authors:  Alberto Francisco Rubio-Guerra; Hilda Vargas-Robles; Luz Maria Ramos-Brizuela; Bruno Alfonso Escalante-Acosta
Journal:  Integr Blood Press Control       Date:  2010-09-29

Review 5.  Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease.

Authors:  Mark J Crabtree; Keith M Channon
Journal:  Nitric Oxide       Date:  2011-04-22       Impact factor: 4.427

Review 6.  Tetrahydrobiopterin in cardiovascular health and disease.

Authors:  Jennifer K Bendall; Gillian Douglas; Eileen McNeill; Keith M Channon; Mark J Crabtree
Journal:  Antioxid Redox Signal       Date:  2014-03-14       Impact factor: 8.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.